SA trial shows J&J vaccine is effective against Delta strain
Sisonke study involving 480,000 health workers provides the first large-scale evidence that the J&J vaccine is effective against the dominant variant
06 August 2021 - 11:57
Johnson & Johnson’s (J&J) Covid-19 vaccine helps prevent severe disease among those infected with the Delta variant, according to a trial involving almost 480,000 health workers in SA.
The study, known as Sisonke, provides the first large-scale evidence that the J&J vaccine is effective against this dominant variant, according to trial co-lead Glenda Gray. It’s probably more protective against Delta than it was with the earlier Beta strain, she said in a presentation Friday. ..
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
This article is free to read if you sign up or sign in.
If you have already registered or subscribed, please sign in to continue.
Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00.